The bar here is remarkably low. Nobody gets excited about packaged food, which is precisely how a company ends up trading at half its estimated value while insiders are buying.
Stay with this, and you will know what has to stabilise before the multiple repairs itself.
Hidden AI Picks (Sponsored)
The obvious AI winners have already made headlines.
Chief Investment Strategist Alexander Green with The Oxford Club believes the next wave could come from three lesser-known companies quietly dominating cybersecurity, retail automation and pharma.
He says investors should know these names before December 2026.
Click here to learn more
Shipping
ZIM Trades 22% Below Its $35 Buyout as Hapag-Lloyd Tries to Save the Deal
ZIM Integrated Shipping Services Ltd. (NYSE: ZIM) has a fresh catalyst after Hapag-Lloyd revised the structure of its proposed $4.2 billion acquisition to address Israeli government concerns. The existing cash offer remains $35 per share, roughly 22% above ZIM’s last close near $28.58.
The deal alone does not support the discount. ZIM ended June with about $2.53 billion in total cash, generated $621 million of free cash flow during the first half, and currently trades below book value at roughly 0.9 times equity.
Operating results have also improved, with Q2 revenue up 9% and adjusted EBITDA reaching $491 million. Management expects $2.0 billion to $2.4 billion of adjusted EBITDA this year, giving you a profitable standalone business underneath the merger spread.
A Revised Deal Could Unlock the Discount
Hapag-Lloyd is proposing additional safeguards that would keep strategically important operations under Israeli control, directly targeting the biggest obstacle to approval. If those concessions satisfy regulators, your upside has a clearly defined $35 cash endpoint rather than depending entirely on the market assigning ZIM a higher multiple.
Shipping Cycles Keep the Risk High
A rejected transaction would remove that valuation anchor immediately, while container freight rates can produce dramatic swings in earnings and cash flow. Still, with substantial liquidity, positive free cash flow, and shares already below book value, you do not need the takeover to be the only reason ZIM looks discounted.
Healthcare
Phreesia Trades Near 5x Guided EBITDA as Cash Flow Keeps Improving
Phreesia Inc. (NYSE: PHR) is coming off a post-earnings selloff even though Q2 revenue increased 10% to $129.5 million and adjusted EBITDA jumped 49% to $32.9 million. The company also maintained its full-year adjusted EBITDA outlook of $125 million to $135 million.
Around $10.94, Phreesia carries an enterprise value near $665 million. Against the $130 million midpoint of adjusted EBITDA guidance, the healthcare software company trades at only about 5 times current-year EBITDA.
Profitability is improving alongside cash generation. Q2 free cash flow increased to $13.8 million, operating cash flow reached $18.3 million, and Phreesia repaid more than $23 million of debt while finishing July with $74.6 million of cash.
Profit Growth Is Outrunning Revenue
Phreesia does not need explosive sales growth to make today’s valuation interesting if margins continue expanding. Healthcare-services clients rose 6%, revenue per client increased 4%, and products including AccessOne and ProviderConnect offer additional growth avenues, giving you several ways for improving operating leverage to translate into higher cash generation.
The Discount Still Has Reasons
Revenue visibility in parts of the business remains uneven, and the company has relied heavily on stock-based compensation, which can dilute existing shareholders. Those risks deserve a discount, but your valuation starting point is now around 5 times guided adjusted EBITDA while revenue, profitability, and free cash flow are all moving higher, creating a much stronger setup than the stock’s recent decline suggests.
AI warning (Sponsored)
Artificial intelligence is creating enormous opportunities—but some investors are also preparing for a very different future.
One veteran market analyst believes the next wave of AI could dramatically reshape the economy, and he's released a free briefing outlining the trends he's watching and the strategy he believes investors should understand.
Watch the Free Briefing.
Industrials
Quanex Still Trades Near 10x Next-Year Earnings After Repaying $42 Million of Debt
Quanex Building Products Corp. (NYSE: NX) jumped after fiscal Q3 results beat expectations, with adjusted EPS reaching $0.79 and adjusted EBITDA climbing to $72.7 million. Management also expects another 50 to 75 basis points of margin expansion in Q4 despite continued weakness across housing-related markets.
Even after the rally, Quanex trades near 10 times next-year consensus earnings. The valuation remains modest for a company improving profitability before receiving much help from a broader recovery in residential construction.
Balance-sheet progress adds another layer to the story. Quanex repaid $42.25 million of debt during Q3, bringing net leverage down to roughly 2.8 times adjusted EBITDA, while management continues targeting further reductions.
Better Margins Can Arrive Before Housing Recovers
Gross margin improved to 28.2% in Q3, while adjusted EBITDA margin reached 14.5% as pricing and cost actions gained traction. If those improvements hold while debt continues falling, you have a path toward stronger equity value even without assuming an immediate rebound in housing demand.
The Cycle Still Sets the Limits
Nine-month adjusted EBITDA remains below last year’s level, leverage is still meaningful, and housing weakness could persist longer than expected. Your upside therefore depends on management protecting margins and continuing to repair the balance sheet, but near 10 times next-year earnings, Quanex does not require an aggressive recovery scenario for the valuation to remain interesting.
Actionable Picks This Week
Conagra Brands (NYSE: CAG)
Open your freezer. Something in there came from this company, and you did not think about it once while buying it, which is how a business ends up trading at roughly half its estimated fair value. Management bought around $0.6 million of stock over a recent three-month stretch, which is not a headline number but does tell you where the people running the place think the price sits.
The upside mechanism is unusually undemanding here, because margins do not need to become impressive; they need to stop getting worse. Once the cost cadence stabilises, the dividend and buyback math starts compounding without anyone having to do anything clever.
One flag: this carries a possible value trap label, so the discount is real, but it could sit there a while. Build on weakness under $15 and hold through the next two prints rather than expecting a quick move.
UiPath (NYSE: PATH)
Friday's drop handed you back an entry that had already closed once, after the stock ran nearly 60% in a month through late August, went briefly expensive, then gave it all back on guidance that underwhelmed.
What the selloff obscures is the underlying quality, because this scores 82 out of 100 on overall business health, with financial strength rated 8 out of 10, which is a genuinely strong balance sheet for a company the market treats as broken.
BMO just raised its target to $18 from $13 while holding a neutral rating, an unusual combination that tells you the analyst sees the numbers improving faster than the story. The bet is simple: growth reaccelerates as AI agent adoption picks up, or it does not. Gross retention is steady, and the balance sheet buys management time to find out. Skip this if another quarter of choppy commentary would rattle you out of the position.
Chewy (NYSE: CHWY)
Wednesday morning is the whole event here, and sentiment going in is poor. The bear case has been identical for a year: that Amazon eats everything eventually, but what that misses is that autoship customers are not really shopping at all; they are running a subscription they set up once and stopped thinking about. That behaviour is far stickier than price comparison, which is the only lever Amazon actually pulls.
Meanwhile, the Canadian expansion is working, and the vet care rollout is real rather than aspirational, both of which drag the business away from commodity retail toward something with switching costs.
The setup is genuinely two-sided: a beat with a reiterated outlook re-rates this fast because so little optimism is priced in, while a miss hands you a better entry than you have today. Either way, Wednesday tells you, so a starter position now with room to add afterward is the sensible structure.
Tax Strategy (Sponsored)
Many investors overlook deductions that could help minimize capital gains tax, such as:
Eligible investment expenses
Selling costs tied to property
Each comes with IRS rules and reporting requirements.
That’s why consulting a fiduciary financial advisor is often recommended.
See Advisor Matches.
Fast Movers to Watch
Signet Jewelers (NYSE: SIG) Engagement rings are stabilising after a genuinely strange few years, and lab grown stones have finally turned accretive to margin rather than cannibalising it.
The stock trades at a forward earnings multiple around 7.5 against a retail sector median above 15, which is roughly half, with an overall quality score of 80 out of 100. It reports Wednesday, and guidance holding is what moves it.Gap Inc. (NYSE: GAP) The namesake brand posted 9% net sales growth with 10% comparable growth, while Old Navy comps fell 4%, and it is getting a new chief executive, Michael Francis.
That split is important because the market prices this as one struggling retailer when it is really one brand working and one being fixed. The balance sheet holds $2.5 billion in cash and short term investments, and $726 million has gone back to shareholders year to date through dividends and buybacks.PTC Therapeutics (NASDAQ: PTCT) Here rather than in the picks, because the numbers do not support calling it cheap. Intrinsic value estimates sit far below the current price, and the valuation rank is the lowest on the scale.
What is pretty impressive is the pipeline: Sephience has reframed this from an orphan drug shop into something closer to a rare disease platform, votoplam is in Phase 3 with Novartis funding it, and vatiquinone’s study launches this quarter. Own it for the catalysts if you want, but do not tell yourself you are buying a discount.
You've found an asset that appears to be 50% below intrinsic value. The catch: it's completely illiquid — you couldn't sell it for 5 years even if you wanted to. How much of your liquid net worth would you put in?
- 5% max. Illiquidity is a real cost and 5 years is a long time for things to go wrong.
- 10-15% if the thesis is airtight. The illiquidity premium should be compensated at that discount.
- 20%+. At 50% below intrinsic value, illiquidity for 5 years is a minor inconvenience.
- Zero. I don't buy things I can't sell. Period.
Everything Else
A free report names seven stocks with rock solid balance sheets including a healthcare leader that has raised its dividend for 61 consecutive years.
Nvidia remains in focus after agreeing to acquire Hugging Face for nearly $13 billion, adding another potential pipeline of AI-model customers for its processors.
Broadcom remains on watch after forecasting roughly $115 billion in fiscal 2027 AI-chip revenue, up from its previous $100 billion target.
Oracle heads into earnings with options markets implying an unusually large 11.2% potential move as investors debate whether its AI-cloud growth can justify the valuation.
Marvell is benefiting from renewed enthusiasm around custom AI infrastructure, with semiconductor shares extending gains as Asian chip stocks rallied Monday.
That's our coverage for today; thanks for reading! Reply to this email with feedback or any stocks you want me to check out.
Best Regards,
—Noah Zelvis
Undervalued Edge
